189 related articles for article (PubMed ID: 31286464)
1. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of renal cell carcinoma in the US: Part II--an updated analysis.
Shih YC; Chien CR; Xu Y; Pan IW; Smith GL; Buchholz TA
Pharmacoeconomics; 2011 Apr; 29(4):331-41. PubMed ID: 21395352
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
4. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
[TBL] [Abstract][Full Text] [Related]
5. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
7. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.
Saad AM; Gad MM; Al-Husseini MJ; Ruhban IA; Sonbol MB; Ho TH
Clin Genitourin Cancer; 2019 Feb; 17(1):46-57.e5. PubMed ID: 30391138
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
9. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
10. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.
Brown ML; Riley GF; Potosky AL; Etzioni RD
Med Care; 1999 Dec; 37(12):1249-59. PubMed ID: 10599606
[TBL] [Abstract][Full Text] [Related]
11. The burden of illness associated with hepatocellular carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Shah S; Thompson D
J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data.
Bhandari NR; Kale HP; Carroll NV; McAdam-Marx C; Ounpraseuth ST; Tilford JM; Kamel MH; Kent EE; Payakachat N
Urol Oncol; 2022 Jul; 40(7):347.e17-347.e27. PubMed ID: 35643842
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.
Chien CR; Geynisman DM; Kim B; Xu Y; Shih YT
Pharmacoeconomics; 2019 Mar; 37(3):301-331. PubMed ID: 30467701
[TBL] [Abstract][Full Text] [Related]
14. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
16. Incidence, predictors, costs, and outcome of renal cell carcinoma after kidney transplantation: USRDS experience.
Hurst FP; Jindal RM; Graham LJ; Falta EM; Elster EA; Stackhouse GB; Agodoa LY; Lentine KL; Salifu MO; Abbott KC
Transplantation; 2010 Oct; 90(8):898-904. PubMed ID: 21248500
[TBL] [Abstract][Full Text] [Related]
17. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C
Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
19. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]